Is adagrasib available in China? Is it covered by domestic medical insurance?

Adagrasib, a new targeted therapy drug, was recently approved by the U.S.FDA for the treatment of specific types of cancer. The drug offers new hope for patients whose cancer has spread to other parts of the body or cannot be removed with surgery.

For patients with non-small cell lung cancer (NSCLC) whose disease has progressed to an advanced stage and the presence of the KRAS G12C mutation is confirmed by an FDA-approved test, adagrasib will be an effective treatment option. However, these patients must have already tried at least one systemic treatment. In this case, adagrasib will be used as a single agent to target the KRAS G12C mutation.

Additionally, adagrasib may also play a therapeutic role in patients with metastatic colorectal cancer (CRC) whose disease has also spread or is inoperable and whose KRAS G12C mutation is confirmed by an FDA-approved test. However, unlike the treatment of NSCLC, when treating CRC, adagrasib needs to be used in combination with cetuximab to achieve the best therapeutic effect. These patients must also have tried fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Since adagrasib has not yet been launched in the domestic market, it cannot be included in the scope of domestic medical insurance reimbursement. However, there is good news recently: the first generic version of adagrasibu has been launched in Laos. This initiative brings new hope to patients around the world, especially those patient families who have to give up treatment due to the high price of original drugs. This generic drug launched in Laos has successfully broken the price barrier of the original drug, reducing the monthly treatment cost from 200,000 yuan to 8,000 to 9,000 yuan. For more questions about adagrasib, patients are advised to consult a professional overseas medical consulting agency.

Overall, the approval of adagrasib provides a new treatment strategy for patients with advanced and difficult-to-treat cancer. By targeting the KRAS G12C mutation, this drug is expected to extend patients' survival and improve their quality of life. However, it is important to note that each patient's specific situation needs to be evaluated by a professional physician to ensure that the treatment plan is individualized and optimized.